Biotron to present HIV trial data at IAS 2013
Biotron (ASX:BIT) has been chosen to present details of a phase IIa trial of antiviral candidate BIT225 at this year’s IAS Conference on HIV Pathogenesis, Treatment and Prevention.
The conference is this year being held in Malaysia from 28 June to 3 July. Biotron will present at the conference proper, as well as the preceding ‘Towards an HIV Cure’ symposium.
“This is an important opportunity to highlight and expand on the encouraging results we have achieved to date with BIT225 in HIV-infected patients,” Biotron managing director Dr Michelle Miller said.
The phase IIa trial was conducted in Bangkok and involved 21 HIV patients with high levels of virus, good CD4+ T cell counts and no prior exposure to antiretroviral drugs.
Preliminary results announced in March support BIT225’s potential to target HIV reservoir precursor cells.
The company is also trialling BIT225 in hepatitis C (HCV) and in patients co-infected with HIV and HVC.
Biotron shares were trading unchanged at $0.10 as of around 1 pm on Friday.
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
Existing medicines could help treat deadly childhood dementia
Australian researchers have identified several existing TGA‑approved medicines that could help...
Statins reduce heart attack and stroke risk in older people
It has previously been unclear whether statins were effective in reducing heart attack and stroke...
